Trial reportScience translational medicine2015
Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia.
Trial report in Science translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Response to alemtuzumab-based therapy and long-term survival after allogeneic transplantation in T-Cell prolymphocytic leukemia: a systematic review and meta-analysis of proportions.European journal of clinical pharmacology · 2026Pooled it
- Advances and Perspectives in the Treatment of T-PLL.Current hematologic malignancy reports · 2020Pooled it
- Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Prolymphocytic Leukemia.Journal of clinical medicine · 2025Article
- Histone deacetylase inhibitors for leukemia treatment: current status and future directions.European journal of medical research · 2024Review
- T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment.International journal of molecular sciences · 2023Review
- Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics.Genes & diseases · 2023Review
- Cutaneous Lymphoma and Antibody-Directed Therapies.Antibodies (Basel, Switzerland) · 2023Review
- High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell Lymphoma.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research.Transplantation and cellular therapy · 2022Article
- Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma.Oncotarget · 2022Article
- Mantle cell lymphoma management trends and novel agents: where are we going?Therapeutic advances in hematology · 2022Article
- Article
- Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemia.Scientific reports · 2021Article
- Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia.Blood cancer journal · 2021Article
- Review
- Advanced Pathogenetic Concepts in T-Cell Prolymphocytic Leukemia and Their Translational Impact.Frontiers in oncology · 2021Review
- The potential of brentuximab vedotin, alone or in combination with current clinical therapies, in the treatment of testicular germ cell tumors.American journal of cancer research · 2019Article
- Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs.CNS drugs · 2018Review
- CD30 expression and survival in extranodal NK/T-cell lymphoma: a systematic review and meta-analysis.Oncotarget · 2018Article
- Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.Leukemia · 2018Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
T cell prolymphocytic leukemia (T-PLL) is a rare, mature T cell neoplasm with distinct features and an aggressive clinical course. Early relapse and short overall survival are commonplace. Use of the monoclonal anti-CD52 antibody alemtuzumab has improved the rate of complete remission and duration of response to more than 50% and between 6 and 12 months, respectively. Despite this advance, without an allogeneic transplant, resistant relapse is inevitable. We report seven complete and one partial remission in eight patients receiving alemtuzumab and cladribine with or without a histone deacetylase inhibitor. These data show that administration of epigenetic agents can overcome alemtuzumab resistance. We also report epigenetically induced expression of the surface receptor protein CD30 in T-PLL. Subsequent treatment with the anti-CD30 antibody-drug conjugate brentuximab vedotin overcame organ-specific (skin) resistance to alemtuzumab. Our findings demonstrate activity of combination epigenetic and immunotherapy in the incurable illness T-PLL, particularly in the setting of previous alemtuzumab therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.